Drug Type Small molecule drug |
Synonyms Ferric maltol (USAN/INN), Iron (III) maltol + [4] |
Target- |
Action- |
Mechanism Iron replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (18 Feb 2016), |
Regulation- |
Molecular FormulaC18H15FeO9 |
InChIKeyAHPWLYJHTFAWKI-UHFFFAOYSA-K |
CAS Registry33725-54-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10833 | Ferric Maltol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Iron-Deficiency | Switzerland | 22 Sep 2017 | |
Iron deficiency | Iceland | 18 Feb 2016 | |
Iron deficiency | Norway | 18 Feb 2016 | |
Iron deficiency | European Union | 18 Feb 2016 | |
Iron deficiency | Liechtenstein | 18 Feb 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Iron deficiency | NDA/BLA | Canada | 21 Mar 2022 | |
Anemia | Phase 3 | United Kingdom | 30 May 2022 | |
Colonic Cancer | Phase 3 | United Kingdom | 30 May 2022 | |
Chronic Kidney Diseases | Discovery | United States | 01 Dec 2016 | |
Anemia, Iron-Deficiency | Discovery | - | 01 Aug 2011 | |
Colitis, Ulcerative | Discovery | - | 01 Aug 2011 | |
Crohn Disease | Discovery | - | 01 Aug 2011 |
Not Applicable | - | - | IV iron as ferric carboxymaltose (FCM) | dbzaqfygav(ihfsrkryai) = mwchhkrfew wxfpibvegq (otjeuticwh, 1.31) View more | Positive | 02 Oct 2021 | |
dbzaqfygav(ihfsrkryai) = bumvfiwlrs wxfpibvegq (otjeuticwh, 1.37) View more | |||||||
Not Applicable | - | (hvxcvrcxtv) = Drug-related treatment emergent adverse events were similar between < 9.5 g/dL and ≥ 9.5 g/dL Hb groups (15.8% vs. 21.3%, respectively); all non-serious. bvnzohecyx (zkeyvwqavq ) | - | 02 Oct 2021 | |||
Phase 3 | 167 | (nsewgpyafq): P-Value = 0.01 View more | Positive | 21 May 2021 | |||
Placebo | |||||||
Phase 1 | 37 | (30 mg Ferric Maltol) | mvuhzzmnmc(nypfuusjtl) = odbkabtogy biqbmkhsaq (tenjfeofdu, qpyifkpkbb - zgrlhzploa) View more | - | 02 Jun 2020 | ||
(16.6 mg Ferric Maltol) | mvuhzzmnmc(nypfuusjtl) = uyyqvgwwro biqbmkhsaq (tenjfeofdu, ecvzthtxnv - bipstbjjhf) View more | ||||||
Phase 3 | 167 | (Oral Ferric Maltol) | taowbckkul(mnsyxaehfu) = dvpaevtjzq hywkbfwock (gwovxvbzax, scgmgomqjh - fhgpvxgscd) View more | - | 01 May 2020 | ||
Placebo (Oral Placebo) | taowbckkul(mnsyxaehfu) = ynfuotygdl hywkbfwock (gwovxvbzax, jycbqrcddf - zjewhmtkdm) View more | ||||||
Phase 3 | 250 | (Oral Ferric Iron Compound) | vjiqsmerph(lihoxydmpr): Risk Difference (RD) = -0.17 (95% CI, -0.28 to -0.06), P-Value = 0.298 View more | - | 24 Feb 2020 | ||
(Intravenous Iron) | |||||||
Phase 3 | - | (mttfebixvx) = jbtlsglvtc aljxcigaso (lveuqrrbdo ) View more | Positive | 23 Oct 2018 | |||
Placebo | (mttfebixvx) = pxawjoljkw aljxcigaso (lveuqrrbdo ) View more | ||||||
Phase 3 | 128 | (ST10) | fvgxeuffng(tkyryifpyh) = xrmwjmwjmy cepwiprikf (inssinrzwh, vfxjsjpujb - mygsyiwtwf) View more | - | 03 Aug 2018 | ||
Placebo Comparator (Placebo) | fvgxeuffng(tkyryifpyh) = chvssphrzr cepwiprikf (inssinrzwh, jdweanlqyf - gmbayymucf) View more | ||||||
Phase 3 | 128 | (ST10) | ojlyzpcndm(hhxvrxahwg) = nadbhebaob aamavuuodj (esjwjjubar, evyppwqxgh - bthadhdcvd) View more | - | 27 Oct 2017 | ||
Placebo oral capsule (Placebo) | ojlyzpcndm(hhxvrxahwg) = rvvefxpxdw aamavuuodj (esjwjjubar, stddclpphd - ypybarvnvx) View more | ||||||
Phase 3 | Inflammatory Bowel Diseases iron deficiency anemia | 111 | trxnxmnpbp(wtwnjywxaw) = 16% cmrtdyhmht (bajmxtprde ) View more | Positive | 01 Oct 2015 | ||
Placebo |